Recombinant Human BCMA/TNFRSF17 (Recombinant Human B-Cell Maturation Antigen; rHuBCMA);重组人B细胞成熟抗原/TNFRSF17
Synonyms
CD269; TNFRSF17; B cell maturation antigen; B-cell maturation protein; BCMAtumor necrosis factor receptor superfamily member 17; BCMB-cell maturation factor; CD269; CD269 antigen; tumor necrosis factor receptor superfamily, member 17
Purity
>98% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40ng/ml, corresponding to a specific activity of >2.5×104IU/mg in the presence of 100ng/ml human APRIL.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μM filtered concentrated solution in 30% acetonitrile, 0.1% TFA.
Endotoxin
Less than 1EU/μg of rHuBCMA as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
B-Cell Maturation Antigen (BCMA), encoded by the TNFRSF17 gene in humans. It is a member of the TNF receptor superfamily and a type III membrane protein containing one extracellular cysteine rich domain. It is expressed on mature B-cells and other B-cell lines. BCMA can binds to TNFSF13B/BLyS/BAFF and TNFSF13/APRIL, and has functions that promotes Bcell survival, plays a role in the regulation of humoral immunity, and activates NF-kappa-B and JNK BCMA.